Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
During the UKPDS, there was a 16% reduction in CVD events (combined fatal or nonfatal MI and sudden death) in the intensive glycemic control arm that did not reach statistical significance ( P = 0.052), and there was no suggestion of benefit on other CVD outcomes (e.g., stroke)
It is better understood as a lower-intensity strategy that may support appetite control, cravings, and consistency while preserving the option to adjust later if clinically appropriate
Long-term success depends on consistent medication use and maintaining healthy lifestyle habits
A systematic review conducted by the scientists at Staten Island University Hospital, US, describes the utility of glucagon-like peptide-1 receptor agonists in reducing binge eating behaviors in individuals with binge eating disorder and bulimia nervosa
Medicare Part D now covers select weight loss medications for eligible beneficiaries, a significant change from the historical exclusion of anti-obesity drugs
doi: 10.2217/fmb-2019-0343 156 SuS.YanH.MinL.WangH.ChenX.ShiJ.et al
